[{"orgOrder":0,"company":"Azafaros","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azafaros Completes EUR 25 Million Series A Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Azafaros"},{"orgOrder":0,"company":"VectorY","sponsor":"Wageningen University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wageningen University & Research and VectorY to Jointly Develop Novel Production Technologies for Safer and More Affordable Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"VectorY"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
The strategy is based on the baculovirus expression system, which is already widely used for vaccine production and uses viruses that can only infect insect cells, the so-called baculoviruses.
The financing helps Azafaros to build its organization and expand its executive team with passionate and experienced people and to advance its rare metabolic disorders pipeline.